PMID- 11355950
OWN - NLM
STAT- MEDLINE
DCOM- 20010628
LR  - 20220419
IS  - 0007-0920 (Print)
IS  - 1532-1827 (Electronic)
IS  - 0007-0920 (Linking)
VI  - 84
IP  - 10
DP  - 2001 May 18
TI  - Expression and clinical significance of erb-B receptor family in hepatocellular 
      carcinoma.
PG  - 1377-83
AB  - In order to elucidate the clinical significance of the erbB family, epidermal 
      growth factor receptor (EGF-R), c-erbB-2, c-erbB-3 and c-erbB-4 in hepatocellular 
      carcinoma (HCC), we investigated the expression of these proteins by means of 
      immunohistochemistry for HCC as well as adjacent noncancerous lesions. EGF-R was 
      expressed in 68% of the HCC examined and showed correlation with the 
      proliferating activity, stage, intrahepatic metastasis and carcinoma 
      differentiation. c-erbB-2 was expressed in only 21% of the cases and showed no 
      relationships with the clinicopathological parameters. c-erbB-3 protein was 
      observed in 84% of the HCC and 38.1% of the noncancerous lesions. Its expression 
      in HCC was equal to or greater than noncancerous lesions in 90.5% of the cases, 
      and was related to the stage, portal invasion, cell proliferating activity, 
      tumour size, intrahepatic metastasis and carcinoma differentiation. c-erbB-4 
      protein was expressed in 61.0% of HCC and in as much as 86.1% of the noncancerous 
      lesions. Unlike the expression of c-erbB-3, that of c-erbB-4 in HCC was less than 
      that of the adjacent noncancerous lesions in 51.2% of the cases. No statistical 
      significance could be established between this protein expression in HCC and 
      clinicopathological features. EGF-R and c-erbB-3 affected disease-free survival, 
      but were not recognized as independent prognostic factors by multivariate 
      analysis. The present study suggests that, of the four receptors, EGF-R and 
      c-erbB-3 play important roles in the progression of HCC.
CI  - Copyright 2001 Cancer Research Campaign.
FAU - Ito, Y
AU  - Ito Y
AD  - Department of Surgery, Osaka Seamen's Insurance Hospital, 1-8-30, Chikko, 
      Minato-ku, Osaka, 552-0021, Japan.
FAU - Takeda, T
AU  - Takeda T
FAU - Sakon, M
AU  - Sakon M
FAU - Tsujimoto, M
AU  - Tsujimoto M
FAU - Higashiyama, S
AU  - Higashiyama S
FAU - Noda, K
AU  - Noda K
FAU - Miyoshi, E
AU  - Miyoshi E
FAU - Monden, M
AU  - Monden M
FAU - Matsuura, N
AU  - Matsuura N
LA  - eng
PT  - Journal Article
PL  - England
TA  - Br J Cancer
JT  - British journal of cancer
JID - 0370635
RN  - EC 2.7.10.1 (ERBB4 protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.10.1 (Receptor, ErbB-3)
RN  - EC 2.7.10.1 (Receptor, ErbB-4)
SB  - IM
MH  - Carcinoma, Hepatocellular/*pathology/surgery
MH  - Disease-Free Survival
MH  - ErbB Receptors/*analysis
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunohistochemistry
MH  - Liver/pathology
MH  - Liver Neoplasms/*pathology/surgery
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Metastasis
MH  - Receptor, ErbB-2/*analysis
MH  - Receptor, ErbB-3/*analysis
MH  - Receptor, ErbB-4
MH  - Retrospective Studies
MH  - Time Factors
PMC - PMC2363640
EDAT- 2001/05/18 10:00
MHDA- 2001/06/29 10:01
CRDT- 2001/05/18 10:00
PHST- 2001/05/18 10:00 [pubmed]
PHST- 2001/06/29 10:01 [medline]
PHST- 2001/05/18 10:00 [entrez]
AID - S0007092000915805 [pii]
AID - 10.1054/bjoc.2000.1580 [doi]
PST - ppublish
SO  - Br J Cancer. 2001 May 18;84(10):1377-83. doi: 10.1054/bjoc.2000.1580.